Sandoz Inc. v. Amgen Inc.
From Wikipedia, the free encyclopedia
| Sandoz Inc. v. Amgen Inc. | |
|---|---|
 | |
| Decided June 12, 2017 | |
| Full case name | Sandoz Inc. v. Amgen Inc. |
| Docket no. | 15-1039 |
| Citations | 582 U.S. 1 (more) |
| Holding | |
| Section 262(l)(2)(A) of the Biologics Price Competition and Innovation Act of 2009 is not enforceable by injunction under federal law. An applicant may provide notice under Section 262(l)(8)(A) prior to obtaining licensure. | |
| Court membership | |
| |
| Case opinion | |
| Majority | Thomas, joined by unanimous |
| Laws applied | |
| Biologics Price Competition and Innovation Act of 2009 | |
Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017), was a United States Supreme Court case in which the court held that Section 262(l)(2)(A) of the Biologics Price Competition and Innovation Act of 2009 is not enforceable by injunction under federal law. An applicant may provide notice under Section 262(l)(8)(A) prior to obtaining licensure.[1][2]
